Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 plus paclitaxel versus placebo plus paclitaxel in HER2-negative advanced or metastatic breast cancer
NL-OMON39231Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing BKM120 plus paclitaxel with Placebo plus paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Oct 2012; status: active, not recruiting.
02
Drugs
buparlisibpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON39231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39231.